Quetiapine Fumarate XR Tablets
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
DLA TROOP SUPPORT
Contract Value
Not provided
Codes & Classification
Solicitation Number
SPE2D223R0010
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
Documents4
The Defense Logistics Agency (DLA) Troop Support has issued a solicitation (SPE2D223R0010) for the supply of Quetiapine Fumarate XR Tablets, classified under NAICS code 325412 (Pharmaceutical Preparation Manufacturing, 2022 version) and Product Service Code 6505 (Drugs and Biologicals). This procurement seeks qualified manufacturers or suppliers capable of providing extended-release Quetiapine Fumarate tablets, a pharmaceutical product commonly used in the treatment of certain mental health conditions.
The primary objective of this solicitation is to secure a reliable source of Quetiapine Fumarate XR Tablets to support the medical needs of federal entities, ensuring consistent availability and compliance with applicable quality standards. The scope encompasses the manufacturing, packaging, and delivery of the specified pharmaceutical product in accordance with federal requirements. Contractors are expected to meet all regulatory standards for pharmaceutical preparation, including those related to safety, efficacy, and labeling.
Amendments to the solicitation have been issued to update key parameters. Amendment 0001, dated April 12, 2023, revised the size standard for the applicable NAICS code from 1,250 to 1,300 employees, potentially affecting eligibility for small business set-aside considerations. Subsequent amendments (0002 and 0003) extended the response deadline, with the current closing date set for May 19, 2023, at 3:00 PM EDT. These extensions provide additional time for interested parties to prepare and submit their proposals.
The contracting entity for this opportunity is DLA Troop Support, a federal office responsible for the procurement and distribution of medical supplies to support military and other federal operations. The primary point of contact for this solicitation is Phyllis Daraio, who can be reached at [email protected] or by phone at 215-737-7941 for further information or clarification regarding the requirements.
The solicitation is currently active and posted on SAM.gov, with four attachments available for review. Interested contractors are encouraged to carefully examine all solicitation documents and amendments to ensure compliance with submission requirements and eligibility criteria. The opportunity is suitable for organizations with established capabilities in pharmaceutical manufacturing, particularly those experienced in producing extended-release formulations.
No specific set-aside requirements or special considerations beyond the updated size standard have been indicated in the provided information. Contractors should note that the fundamental requirements—manufacturing and supplying Quetiapine Fumarate XR Tablets in accordance with federal standards—will remain constant throughout the contract lifecycle.
For full details and to access solicitation documents, contractors should refer to the official notice at: https://sam.gov/opp/5638f6e61f4442d28dd36c7811458ddd/view.